Linked Life Data

11904957

Source:http://linkedlifedata.com/resource/pubmed/id/11904957

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2002-3-21
pubmed:abstractText
ErbB-2, a member of the epidermal growth factor(EGF) receptor tyrosine kinase family, is often overexpressed and/or amplified in breast, ovarian and gastric cancers, and other malignancies. ErbB-2 is a candidate as one of the best target molecules for cancer therapy. Many anti-ErbB-2 monoclonal antibodies(MoAbs) have been developed. An inhibitory humanized MoAb shows clinical responses in some breast cancer patients, both with MoAb alone and in combination with Cisplatinum or other anti-cancer drugs. A mouse-human chimeric anti-ErbB-2 MoAb CH401 was established and characterized in our laboratory. CH401 is able to kill cancer cells overexpressing ErbB-2 both in vitro and in vivo. The analysis of this tumor growth inhibition by CH401 made it clear that the cytotoxicity was induced by apoptosis. These results may suggest that CH401 has a therapeutic potential for ErbB-2 overexpressing cancers. This approach may be particularly valuable as a new type of cancer therapy.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0047-1852
pubmed:author
pubmed:issnType
Print
pubmed:volume
60
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
451-6
pubmed:dateRevised
2011-7-27
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
[Monoclonal antibody induces apoptosis against cancer cells].
pubmed:affiliation
First Department of Internal Medicine, Sapporo Medical University.
pubmed:publicationType
Journal Article, English Abstract, Review